EN ES
Contact

About us

Tetraneuron Our history

A radically new approach to Alzheimer's Disease

Tetraneuroncorporate video

Our history

2012
Tetraneuron was founded

2013
Identification of therapeutic target. E2F4

2014
Beginning of the proof of concept

2015
Validation of therapeutic target: E2F4DN

2016
Identification of the Leading Compound

2017
Validation of the Leading Compound

2018
Validation of the Leading Compound

2019
Analysis of biological processes modulated by E2F4DN

2020
Method validation of AAV9-E2F4DN

2021
Beginning of preclinical regulatory Phase

Tetraneuron is a Spanish gene therapy biotech company with a focus on brain and neurodegenerative conditions

Our team

Team
Advisory Team

José María Frade. PhD

Scientific Director and Co-Founder
Noelia López Sánchez. PhD

Technical Director
David Mor

Interim Managemet
Mari Carmen Álvarez. PhD

Project Director
Cristina Sánchez Puelles. PhD

Post Doctoral Researcher

Morgan Ramón Landrau

Pre Doctoral Researcher

Alberto Garrido

Laboratory Technician

Vanesa Cano

Laboratory Technician

Contact

Collaborating Institutions and Societies